01228.HK
CANbridge Pharmaceuticals Inc.
HKSE · Healthcare · Biotechnology · CN
HKD 1.92
−0.52%Year over year
Reported trailing growth
- Revenue
- -41.3%
- EBITDA
- +75.7%
- EBIT
- +72.8%
- EPS
- +104.6%
- Free cash flow
- +68.8%
- Operating cash flow
- +68.8%
Forward estimates
Based on analyst estimates
- Revenue
- -57.8%
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- -14.1%
- EBITDA
- +76.0%
- EBIT
- +72.8%
- Net income
- +103.3%
- EPS
- +102.9%
- Free cash flow
- +68.8%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Dec 1, 2025